ML314CAS# 1448895-09-7 |
- THZ1
Catalog No.:BCC4005
CAS No.:1604810-83-4
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- AZD-5438
Catalog No.:BCC3689
CAS No.:602306-29-6
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- PD 0332991 (Palbociclib) HCl
Catalog No.:BCC3680
CAS No.:827022-32-2
- Palbociclib (PD0332991) Isethionate
Catalog No.:BCC3698
CAS No.:827022-33-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1448895-09-7 | SDF | Download SDF |
| PubChem ID | 53245590 | Appearance | Powder |
| Formula | C24H28N4O3 | M.Wt | 420.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 47 mg/mL (111.77 mM); | ||
| Chemical Name | 2-cyclopropyl-6,7-dimethoxy-4-[4-(2-methoxyphenyl)piperazin-1-yl]quinazoline | ||
| SMILES | COC1=CC=CC=C1N2CCN(CC2)C3=NC(=NC4=CC(=C(C=C43)OC)OC)C5CC5 | ||
| Standard InChIKey | SWEOAXMICIJCQC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H28N4O3/c1-29-20-7-5-4-6-19(20)27-10-12-28(13-11-27)24-17-14-21(30-2)22(31-3)15-18(17)25-23(26-24)16-8-9-16/h4-7,14-16H,8-13H2,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | ML314 is a potent molecule agonist of NTR1 (EC50 = 1.9 μM); showed good selectivity against NTR2 and GPR35, but did not stimulate Ca2+ mobilization.
IC50 value: 1.9 uM (EC50) [1]
Target: NTR1 agonist
Medicinal chemistry optimization of MLS-0233108 led to ML314, the most potent molecule in this second series that exhibited full agonist behavior (100 %) on NTR1 (EC50 = 1.9 μM). ML314 showed good selectivity against NTR2 and GPR35, but did not stimulate Ca2+ mobilization. ML314 is potentially a biased agonist operating via the β-arrestin pathway rather than the traditional Gq coupled pathway. Signaling mediated by β-arrestin has distinct biochemical and functional consequences that may lead to physiological advantages as described below. This probe report describes the discovery and properties of ML301 and summarizes the HTS and follow-up campaign, which identified ML314. References: | |||||
ML314 Dilution Calculator
ML314 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3781 mL | 11.8906 mL | 23.7812 mL | 47.5624 mL | 59.453 mL |
| 5 mM | 0.4756 mL | 2.3781 mL | 4.7562 mL | 9.5125 mL | 11.8906 mL |
| 10 mM | 0.2378 mL | 1.1891 mL | 2.3781 mL | 4.7562 mL | 5.9453 mL |
| 50 mM | 0.0476 mL | 0.2378 mL | 0.4756 mL | 0.9512 mL | 1.1891 mL |
| 100 mM | 0.0238 mL | 0.1189 mL | 0.2378 mL | 0.4756 mL | 0.5945 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ML314 is a potent molecule agonist of NTR1 (EC50 = 1.9 μM); showed good selectivity against NTR2 and GPR35, but did not stimulate Ca2+ mobilization.
- MRS 2693 trisodium salt
Catalog No.:BCC7386
CAS No.:1448858-83-0
- 4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignan
Catalog No.:BCN1563
CAS No.:144881-21-0
- Junipediol B
Catalog No.:BCN6252
CAS No.:144881-19-6
- Resiquimod (R-848)
Catalog No.:BCC4073
CAS No.:144875-48-9
- Garjasmin
Catalog No.:BCN6251
CAS No.:144868-43-9
- Alpiniaterpene A
Catalog No.:BCN7085
CAS No.:1448667-05-7
- Deflazacort
Catalog No.:BCC8928
CAS No.:14484-47-0
- 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Catalog No.:BCC8720
CAS No.:144809-28-9
- L-703,664 succinate
Catalog No.:BCC7437
CAS No.:144776-01-2
- Brachynoside heptaacetate
Catalog No.:BCN6249
CAS No.:144765-80-0
- Clopidogrel Related Compound B
Catalog No.:BCN2688
CAS No.:144750-52-7
- Cyclo(Ala-Phe)
Catalog No.:BCN2411
CAS No.:14474-78-3
- 1-Methyl-aminomethyl naphthalene
Catalog No.:BCC8471
CAS No.:14489-75-9
- 18alpha-Glycyrrhetinic acid
Catalog No.:BCC8328
CAS No.:1449-05-4
- 21-Episerratenediol
Catalog No.:BCN6253
CAS No.:1449-06-5
- 24-Methylenecycloartanone
Catalog No.:BCN7244
CAS No.:1449-08-7
- 24-Methylenecycloartan-3-ol
Catalog No.:BCN6254
CAS No.:1449-09-8
- Androst-5-en-3-ol-7,17-dione acetate
Catalog No.:BCC8822
CAS No.:1449-61-2
- Senexin B
Catalog No.:BCC3990
CAS No.:1449228-40-3
- K145 hydrochloride
Catalog No.:BCC4072
CAS No.:1449240-68-9
- Chlojaponilactone B
Catalog No.:BCN7400
CAS No.:1449382-91-5
- Boeravinone O
Catalog No.:BCN6693
CAS No.:1449384-21-7
- DDR1-IN-1
Catalog No.:BCC5170
CAS No.:1449685-96-4
- DGAT1-IN-1
Catalog No.:BCC5511
CAS No.:1449779-49-0
Discovery of ML314, a Brain Penetrant Non-Peptidic beta-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.[Pubmed:24611085]
ACS Med Chem Lett. 2013 Jul 20;4(9):846-851.
The neurotensin 1 receptor (NTR1) is an important therapeutic target for a range of disease states including addiction. A high throughput screening campaign, followed by medicinal chemistry optimization, led to the discovery of a non-peptidic beta-arrestin biased agonist for NTR1. The lead compound, 2-cyclopropyl-6,7-dimethoxy-4-(4-(2-methoxyphenyl)- piperazin-1-yl)quinazoline, 32 (ML314), exhibits full agonist behavior against NTR1 (EC50 = 2.0 muM) in the primary assay and selectivity against NTR2. The effect of 32 is blocked by the NTR1 antagonist SR142948A in a dose dependent manner. Unlike peptide based NTR1 agonists, compound 32 has no significant response in a Ca(2+) mobilization assay and is thus a biased agonist that activates the beta-arrestin pathway rather than the traditional G q coupled pathway. This bias has distinct biochemical and functional consequences that may lead to physiological advantages. Compound 32 displays good brain penetration in rodents, and studies examining its in vivo properties are underway.
ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse.[Pubmed:27119457]
ACS Chem Biol. 2016 Jul 15;11(7):1880-90.
Pharmacological treatment for methamphetamine addiction will provide important societal benefits. Neurotensin receptor NTR1 and dopamine receptor distributions coincide in brain areas regulating methamphetamine-associated reward, and neurotensin peptides produce behaviors opposing psychostimulants. Therefore, undesirable methamphetamine-associated activities should be treatable with druggable NTR1 agonists, but no such FDA-approved therapeutics exist. We address this limitation with proof-of-concept data for ML314, a small-molecule, brain penetrant, beta-arrestin biased, NTR1 agonist. ML314 attenuates amphetamine-like hyperlocomotion in dopamine transporter knockout mice, and in C57BL/6J mice it attenuates methamphetamine-induced hyperlocomotion, potentiates the psychostimulant inhibitory effects of a ghrelin antagonist, and reduces methamphetamine-associated conditioned place preference. In rats, ML314 blocks methamphetamine self-administration. ML314 acts as an allosteric enhancer of endogenous neurotensin, unmasking stoichiometric numbers of hidden NTR1 binding sites in transfected-cell membranes or mouse striatal membranes, while additionally supporting NTR1 endocytosis in cells in the absence of NT peptide. These results indicate ML314 is a viable, preclinical lead for methamphetamine abuse treatment and support an allosteric model of G protein-coupled receptor signaling.
